IDKmonitor Ustekinumab Drug Level ELISA 96 wells
Therapeutic Drug Monitoring
The IDKmonitor Ustekinumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free Ustekinumab from plasma or serum samples.
The Ustekinumab ELISA is based on a sandwich enzyme immunoassay technique with a Ustekinumab specific capture antibody adsorbed on a microplate and a detection antibody labeled with horseradish peroxidase (HRP).
This test is intended to quantify the amount of free drug (Ustekinumab) to evaluate the efficacy of drug and to investigate Primary non-response and loss of response.
Being able to stratify patients according to whether they are likely to benefit from their Ustekinumab treatment has both clinical and economic advantages because not all patients respond equally to Ustekinumab.
Some patients will respond well with fewer symptoms with a reduction in inflammatory biomarkers (e.g. faecal calprotectin) and endoscopic scores, while others will fail to respond during the induction phase of treatment, or lose response over time.
IDKmonitor® assays from BIOHIT HealthCare are highly specific for the target drug and are used widely for routine clinical and research applications. The IDKmonitor® Ustekinumab Drug Level ELISA helps:
Assess risk of and manage primary non-response
Predict the long term outcome and identify loss of response
Predict response to anti-interleukins 12 and 23 therapy withdrawal
Predict efficacy of re-initiating therapy after drug holiday
Direct the switching to another class of drug
The IDKmonitor® ELISA for the determination of the drug level of ustekinumab (e.g. STELARA®) in EDTA plasma and serum measures free ustekinumab quantitatively, giving the treating physician an opportunity to monitor and optimise therapy.
The assay determines the quantity of free ustekinumab (therapeutic antibody against interleukins 12 and 23) in EDTA plasma or serum samples by capturing the free (unbound) ustekinumab using a specific monoclonal anti-ustekinumab antibody that coats the plate.
Quantifies free Ustekinumab drug levels in Serum and Plasma
Microplate coated with highly specific anti-Ustekinumab Ab
6 calibrators, 2 controls
Capacity for 40 samples in duplicate
Reportable range 4.15-225 ng/ml
Assay time 130 minutes
Automatable on ELISA automates (e.g. Dynex D2)
Highly specific quantification of Ustekinumab
No cross reactivity with a range of compounds with structural similarity to Ustekinumab including Infliximab, Adalimumab, Golimumab, Etanercept, Vedolizumab
May helps predict Primary non-response, loss of response, non remission
Applicable to Gastroenterology, Rheumatology
+2 to +8